Brainstorm Cell Therapeutics Inc.
BCLI
$1.22
-$0.0001-0.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -9.79% | -6.57% | 25.29% | 39.03% | -354.98% |
| Total Depreciation and Amortization | -10.17% | -7.81% | 0.00% | -3.03% | 1.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 133.80% | -211.34% | 14.12% | -97.47% | 259.29% |
| Change in Net Operating Assets | 514.52% | -172.33% | 476.92% | 102.32% | -333.24% |
| Cash from Operations | 68.23% | -96.02% | 45.05% | 6.76% | 48.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 1,883.33% |
| Cash from Investing | -- | -- | -- | -- | 1,733.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 72.12% | -24.25% | -52.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 72.12% | -24.25% | -52.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.67% | -222.78% | 612.79% | -299.24% | -61.09% |